Otros idiomas Senti Biosciences, Inc.

Acciones

SNTI

US81726A1007

Precio de cierre Nasdaq Otros sitios de cotización 00:00:00 25/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,2787 ^USD	-0,78 %		-9,37 %	-57,77 %

26/04	Senti Biosciences, Inc. anuncia la dimisión de Deborah Knobelman como tesorera y responsable de desarrollo corporativo, con efecto a partir del 3 de mayo de 2024	CI
21/03	Senti Biosciences, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21/03
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05/01
Spark Therapeutics, Inc. Announces Workforce Reduction	05/01
Top Premarket Gainers	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	13/11
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	13/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	06/11
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	31/10/23
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	31/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Senti Biosciences, Inc.

Acciones

SNTI

US81726A1007

Otros idiomas

Filtros